Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 18%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is projected to have a strong financial performance due to their leading position in the growing sleep and respiratory care market, expansion into digital health, and focus on R&D. However, there are potential risks such as increased competition and changes in reimbursement levels. Their latest quarter saw strong growth in international markets but weaker performance in the Americas, demonstrating the company's global presence. Overall, ResMed has a positive outlook as they continue to innovate and adapt to the changing landscape of the healthcare industry.

Bears say

ResMed is facing challenges in sustaining its growth in revenues and earnings with a decreasing gross margin, mainly due to component cost inflation and higher freight costs, and a shift in product mix towards lower-margin devices in the Americas. Additionally, the company's guidance for FY27 sales and earnings falls below market expectations, showcasing potential for slower growth in the future. With increased transparency and disclosures from management, the company's plan for growth through digital health may not be as successful in differentiating itself in the highly competitive respiratory care market.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 18% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.